Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT.

Frontiers in nephrology Pub Date : 2025-04-29 eCollection Date: 2025-01-01 DOI:10.3389/fneph.2025.1548679

Baike Mao, Jiahui Han, Jia Wang, Kan Ye

{"title":"Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT.","authors":"Baike Mao, Jiahui Han, Jia Wang, Kan Ye","doi":"10.3389/fneph.2025.1548679","DOIUrl":null,"url":null,"abstract":"Background: Membranous nephropathy (MGN) represents a significant challenge in nephrology, with Rituximab emerging as a potential therapeutic intervention.Methods: A comprehensive systematic review was conducted using PubMed, EMBASE, and Web of Science databases, focusing exclusively on randomized controlled trials (RCTs) from January 2002 to November 2024. Stringent eligibility criteria were applied, including studies with at least ten participants, with data extracted by two independent reviewers. The meta-analysis utilized fixed and random effects models to assess Rituximab's efficacy and safety across multiple outcome measures.Results: The meta-analysis revealed nuanced findings across different follow-up periods. At 6 months, complete remission rates showed non-significant odds ratios ranging from 2.12 to 2.48. By 12 months, the pooled odds ratio was 0.8085 (95% CI: 0.2238-2.9213), with complete remission rates varying between 13.8% and 19.4%. Notably, at 24 months, the common effects model demonstrated a statistically significant odds ratio of 5.0792 (95% CI: 2.2609-11.4107, p < 0.0001). Proteinuria reduction showed consistent improvement, with a median difference of 4.3225. Adverse event analysis indicated a relatively low risk, with an odds ratio of 0.9706 (95% CI: 0.5781-1.6297).Conclusion: Rituximab demonstrates potential efficacy in treating MGN, with promising long-term outcomes and a favorable adverse event profile.","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1548679"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fneph.2025.1548679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Membranous nephropathy (MGN) represents a significant challenge in nephrology, with Rituximab emerging as a potential therapeutic intervention.

Methods: A comprehensive systematic review was conducted using PubMed, EMBASE, and Web of Science databases, focusing exclusively on randomized controlled trials (RCTs) from January 2002 to November 2024. Stringent eligibility criteria were applied, including studies with at least ten participants, with data extracted by two independent reviewers. The meta-analysis utilized fixed and random effects models to assess Rituximab's efficacy and safety across multiple outcome measures.

Results: The meta-analysis revealed nuanced findings across different follow-up periods. At 6 months, complete remission rates showed non-significant odds ratios ranging from 2.12 to 2.48. By 12 months, the pooled odds ratio was 0.8085 (95% CI: 0.2238-2.9213), with complete remission rates varying between 13.8% and 19.4%. Notably, at 24 months, the common effects model demonstrated a statistically significant odds ratio of 5.0792 (95% CI: 2.2609-11.4107, p < 0.0001). Proteinuria reduction showed consistent improvement, with a median difference of 4.3225. Adverse event analysis indicated a relatively low risk, with an odds ratio of 0.9706 (95% CI: 0.5781-1.6297).

Conclusion: Rituximab demonstrates potential efficacy in treating MGN, with promising long-term outcomes and a favorable adverse event profile.

查看原文本刊更多论文

利妥昔单抗治疗成人膜性肾病的疗效和安全性：一项RCT荟萃分析。

背景：膜性肾病（MGN）在肾脏病学中是一个重大挑战，美罗华（Rituximab）正在成为一种潜在的治疗干预手段。方法：利用PubMed、EMBASE和Web of Science数据库对2002年1月至2024年11月的随机对照试验（rct）进行全面的系统评价。采用严格的资格标准，包括至少有10名参与者的研究，数据由两名独立评论者提取。荟萃分析利用固定效应和随机效应模型来评估利妥昔单抗在多个结果测量中的有效性和安全性。结果：荟萃分析揭示了不同随访期的细微差别。6个月时，完全缓解率的比值比为2.12 - 2.48，无统计学意义。12个月时，合并优势比为0.8085 (95% CI: 0.2238-2.9213)，完全缓解率在13.8%至19.4%之间变化。值得注意的是，在24个月时，共同效应模型显示具有统计学意义的优势比为5.0792 （95% CI: 2.2609-11.4107, p < 0.0001）。蛋白尿减少表现出一致的改善，中位差为4.3225。不良事件分析显示风险相对较低，比值比为0.9706 （95% CI: 0.5781-1.6297）。结论：利妥昔单抗显示出治疗MGN的潜在疗效，具有良好的长期结果和良好的不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in nephrology

自引率

0.00%

发文量